THETFORD MINES, QC, Nov. 17, 2025 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the official opening of its U.S. subsidiary to launch, starting in 2026, the commercialization of Medherize, its therapeutic monitoring platform specialized in oncology. This strategic expansion positions KDA in one of the world's largest specialty drug markets, valued at more than USD 243 billion in 20231.
Read more at newswire.caKDA GROUP OPENS A U.S. SUBSIDIARY AND ACCELERATES THE GROWTH OF ITS MEDHERIZE SOLUTION
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.